Susquehanna International Group, LLP Synthetic Biologics, Inc. Transaction History

Susquehanna International Group, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.9 - $2.9 $39,079 - $59,647	20,568 Added 109.54%	39,345 $8,000
Q1 2022 May 16, 2022	BUY	$2.3 - $4.3 $43,187 - $80,741	18,777 New	18,777 $5,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.5 $59,391 - $98,986	-21,997 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.3 - $5.8 $94,587 - $127,582	21,997 New	21,997 $10,000
Q1 2021 May 17, 2021	SELL	$5.0 - $11.7 $78,525 - $183,748	-15,705 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.9 - $4.6 $45,544 - $72,243	15,705 New	15,705 $6,000
Q2 2020 Aug 14, 2020	SELL	$2.8 - $5.7 $688,508 - $1.4 Million	-245,896 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.7 - $6.1 $663,919 - $1.5 Million	245,896 New	245,896 $79,000
Q4 2019 Feb 14, 2020	SELL	$3.9 - $5.3 $97,379 - $132,335	-24,969 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.9 - $5.9 $57,993 - $87,733	14,870 Added 147.24%	24,969 $11,000
Q2 2019 Aug 14, 2019	SELL	$4.9 - $6.6 $10,843 - $14,605	-2,213 Reduced 17.97%	10,099 $6,000
Q1 2019 May 15, 2019	BUY	$5.9 - $8.1 $72,640 - $99,727	12,312 New	12,312 $8,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.